Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | S100A4 | P26447 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25411924 | 0.84 | ALDH1A1 (0.37) | GPR35TSHRCYP3A4HIF1AALDH1A1 | |
| SCHEMBL7063757 | 0.82 | GPR35 (0.48) | GPR35TP53HPGDTSHRSMN1; SMN2 | |
| SCHEMBL29686335 | 0.80 | VCP (0.40) | TSHRCYP3A4HIF1AMAPK1ALDH1A1 | |
| SCHEMBL1283267 | 0.80 | GPR35 (0.47) | GPR35TP53HPGDTSHRSMN1; SMN2 | |
| SCHEMBL29833724 | 0.80 | GPR35 (0.47) | GPR35TP53HPGDTSHRSMN1; SMN2 | |
| SCHEMBL4582714 | 0.80 | GPR35 (0.47) | GPR35TP53HPGDTSHRSMN1; SMN2 | |
| SCHEMBL16739101 | 0.80 | VCP (0.40) | TSHRCYP3A4HIF1AMAPK1ALDH1A1 | |
| SCHEMBL28259777 | 0.78 | GPR35 (0.55) | GPR35TP53HPGDTSHRSMN1; SMN2 | |
| SCHEMBL19630150 | 0.77 | GPR35 (0.44) | GPR35TP53HPGDTSHRSMN1; SMN2 | |
| SCHEMBL7878527 | 0.77 | GPR35 (0.44) | GPR35TP53HPGDTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49080-E1 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2022-05-24 | — | — | US | disclosed |
| US-9895389-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-20170042925-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20150141354-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| CN-102656165-B | Glycoside derivatives and uses thereof | NOVARTIS AG | 2015-02-11 | — | — | CN | disclosed |
| US-20140274921-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8828951-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-8466114-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2013-06-18 | — | — | US | disclosed |
| US-20130017993-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
| CN-102656165-A | Glycoside derivatives and uses thereof | NOVARTIS AG | 2012-09-05 | — | — | CN | disclosed |
| EP-2491029-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2012-07-12 | — | — | US | disclosed |
| US-8163704-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| WO-2011048112-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042925-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | GPR35 1687/4885TP53 4765/4885HPGD 423/4885 |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | GPR35 1687/4885TP53 4765/4885HPGD 423/4885 |
| US-20150141354-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | GPR35 1687/4885TP53 4765/4885HPGD 423/4885 |
| US-20130017993-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | GPR35 1687/4885TP53 4765/4885HPGD 423/4885 |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | SLC5A1, SLC5A2, SLC2A1 | GPR35 1687/4885TP53 4765/4885HPGD 423/4885 |
| US-20140274921-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | GPR35 1687/4885TP53 4765/4885HPGD 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.